Jeff Johnson
Stock Analyst at Baird
(4.62)
# 195
Out of 5,165 analysts
154
Total ratings
57.14%
Success rate
27.75%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HSIC Henry Schein | Upgrades: Outperform | $78 → $100 | $74.87 | +33.56% | 11 | Feb 23, 2026 | |
| BBNX Beta Bionics | Maintains: Neutral | $28 → $14 | $10.64 | +31.58% | 3 | Feb 18, 2026 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $18 → $30 | $23.91 | +25.47% | 17 | Dec 16, 2025 | |
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $117 → $100 | $92.52 | +8.08% | 15 | Dec 16, 2025 | |
| COO The Cooper Companies | Maintains: Outperform | $85 → $98 | $72.05 | +36.02% | 19 | Dec 5, 2025 | |
| ALC Alcon | Maintains: Outperform | $95 → $98 | $77.78 | +26.00% | 11 | Nov 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $112 → $90 | $67.32 | +33.69% | 15 | Sep 26, 2025 | |
| NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $26.05 | -11.71% | 10 | May 27, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $349.11 | +16.01% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $176.12 | +56.71% | 18 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $230.49 | +3.26% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $23.46 | +198.38% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $13.65 | +346.89% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $12.22 | +448.28% | 6 | Feb 18, 2022 |
Henry Schein
Feb 23, 2026
Upgrades: Outperform
Price Target: $78 → $100
Current: $74.87
Upside: +33.56%
Beta Bionics
Feb 18, 2026
Maintains: Neutral
Price Target: $28 → $14
Current: $10.64
Upside: +31.58%
Tandem Diabetes Care
Dec 16, 2025
Upgrades: Outperform
Price Target: $18 → $30
Current: $23.91
Upside: +25.47%
Zimmer Biomet Holdings
Dec 16, 2025
Downgrades: Neutral
Price Target: $117 → $100
Current: $92.52
Upside: +8.08%
The Cooper Companies
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $98
Current: $72.05
Upside: +36.02%
Alcon
Nov 13, 2025
Maintains: Outperform
Price Target: $95 → $98
Current: $77.78
Upside: +26.00%
DexCom
Sep 26, 2025
Maintains: Outperform
Price Target: $112 → $90
Current: $67.32
Upside: +33.69%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $26.05
Upside: -11.71%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $349.11
Upside: +16.01%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $176.12
Upside: +56.71%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $230.49
Upside: +3.26%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $23.46
Upside: +198.38%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $13.65
Upside: +346.89%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $12.22
Upside: +448.28%